FXN and Friedreich ataxia: A variety of experimental therapies are under investigation for FRDA patients including protein replacement therapy [30], epigenetic-modifying drugs like HDAC inhibitors [31], and synthetic antisense oligonucleotides to increase FXN protein expression [32].